Furthermore, the SIDT2 gene product may contribute to SCD-related outcomes, as its dysregulation is linked to several metabolic traits associated with hepatic disorders, cardiovascular dysfunctions, and SCD-nephropathy (Qian et al., 2023; Geng et al., 2021). This evidence concerns the gene SIDT2 and kidney disorder.